Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Nat Commun. 2023 Nov 25;14(1):7728. doi: 10.1038/s41467-023-43553-z.
Disease-modifying therapies (DMTs) are widely used in neuroimmunological diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Although these treatments are known to predispose patients to infections and affect their responses to vaccination, little is known about the impact of DMTs on the myeloid cell compartment. In this study, we use mass cytometry to examine DMT-associated changes in the innate immune system in untreated and treated patients with MS (n = 39) or NMOSD (n = 23). We also investigated the association between changes in myeloid cell phenotypes and longitudinal responsiveness to homologous primary, secondary, and tertiary SARS-CoV-2 mRNA vaccinations. Multiple DMT-associated myeloid cell clusters, in particular CD64HLADR granulocytes, showed significant correlations with B and T cell responses induced by vaccination. Our findings suggest the potential role of myeloid cells in cellular and humoral responses following vaccination in DMT-treated patients with neuroimmunological diseases.
疾病修正疗法（DMTs）广泛应用于神经免疫性疾病，如多发性硬化症（MS）和视神经脊髓炎谱系障碍（NMOSD）。尽管这些治疗方法已知会使患者易感染，并影响他们对疫苗接种的反应，但对于 DMTs 对髓样细胞区室的影响知之甚少。在这项研究中，我们使用液质联用技术检查了未经治疗和治疗的 MS（n=39）或 NMOSD（n=23）患者的先天免疫系统中与 DMT 相关的变化。我们还研究了髓样细胞表型变化与同源原发性、继发性和 tertiary SARS-CoV-2 mRNA 疫苗接种的纵向反应性之间的关联。多个与 DMT 相关的髓样细胞簇，特别是 CD64HLADR 粒细胞，与疫苗接种诱导的 B 和 T 细胞反应显著相关。我们的研究结果表明，髓样细胞在神经免疫性疾病患者接受 DMT 治疗后，疫苗接种后的细胞和体液反应中可能发挥作用。
